Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice. 4-Year Results From a Large 2-Institutional Cohort Study

Journal of the American College of Cardiology

Volumn 52, Issue 14, 2008, Pages 1134-1140

  Wenaweser, Peter ^a   Daemen, Joost ^b   Zwahlen, Marcel ^a   van Domburg, Ron ^b   Jüni, Peter ^a   Vaina, Sophia ^b   Hellige, Gerrit ^a   Tsuchida, Keiichi ^b   Morger, Cyrill ^a   Boersma, Eric ^b   Kukreja, Neville ^b   Meier, Bernhard ^a   Serruys, Patrick W ^b   Windecker, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

drug eluting stent; mortality; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IN STENT THROMBOSIS; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PACLITAXEL; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SIROLIMUS; SWITZERLAND; TIME FACTORS;

EID: 51649119808     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.07.006     Document Type: Article

References (34)

1. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
2. Serruys P.W., Kutryk M.J., and Ong A.T. Coronary-artery stents. N Engl J Med 354 (2006) 483-495
3. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
4. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
5. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
6. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
7. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
8. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
9. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
10. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
11. Windecker S., and Meier B. Late coronary stent thrombosis. Circulation 116 (2007) 1952-1965
12. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
13. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
14. Cook S., Wenaweser P., Togni M., et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115 (2007) 2426-2434
15. Steffel J., Latini R.A., Akhmedov A., et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112 (2005) 2002-2011
16. Stahli B.E., Camici G.G., Steffel J., et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 99 (2006) 149-155
17. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
18. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
19. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
20. Hofma S.H., van der Giessen W.J., van Dalen B.M., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
21. Kotani J., Awata M., Nanto S., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
22. Togni M., Raber L., Cocchia R., et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 120 (2007) 212-220
23. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
24. James S.J. Drug eluting stents vs bare metal stents in Sweden. http://www.clinicaltrialresults.org Accessed September 5, 2007
25. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
26. Schomig A., Dibra A., Windecker S., et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1373-1380
27. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
28. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
29. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007) 745-754
30. Urban P., Gershlick A.H., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
31. Sianos G., Papafaklis M.I., Daemen J., et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol 50 (2007) 573-583
32. Mehran R., Dangas G.D., Kobayashi Y., et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 43 (2004) 1348-1354
33. Wenaweser P., Dorffler-Melly J., Imboden K., et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45 (2005) 1748-1752
34. Kaul S., Shah P.K., and Diamond G.A. As time goes by: current status and future directions in the controversy over stenting. J Am Coll Cardiol 50 (2007) 128-137